Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | NAAA | Q02083 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466895 | 1.00 | GAA (0.41) | GAAMAPK1HTTSMN1; SMN2BTK | |
| SCHEMBL31246152 | 0.85 | BTK (0.50) | GAAMAPK1BTKCTSKKMT2A | |
| SCHEMBL12962474 | 0.83 | GAA (0.43) | GAAMAPK1HTTSMN1; SMN2BTK | |
| SCHEMBL6466853 | 0.83 | BTK (0.58) | GAAMAPK1HTTSMN1; SMN2BTK | |
| SCHEMBL6466849 | 0.83 | BTK (0.58) | GAAMAPK1HTTSMN1; SMN2BTK | |
| SCHEMBL14750990 | 0.79 | BTK (0.49) | GAAMAPK1BTKEPHX1CTSK | |
| SCHEMBL3645025 | 0.78 | GAA (0.48) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL12640942 | 0.77 | NAAA (0.43) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL31402056 | 0.76 | BTK (0.43) | GAAMAPK1BTKEPHX1CTSK | |
| SCHEMBL31402082 | 0.76 | BTK (0.43) | GAAMAPK1BTKEPHX1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451285-B1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9029377-B2 | Platelet-activating factor receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | PTAFR, PAFAH1B2, PAFAH1B3 | GAA 3461/4885MAPK1 2517/4885HTT 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.